Revenue Performance - Net revenue for Sleep and Respiratory Care products reached $1,017,855 thousand in Q2 2023, a 11% increase from $916,981 thousand in Q2 2022[11] - Total net revenue for the six months ended December 31, 2023, was $2,265,122 thousand, up 14.2% from $1,984,038 thousand in the same period last year[11] - Total net revenue for the company for the three months ended December 31, 2023, was $1,162.8 million, an increase of 12.5% from $1,033.7 million in the same period of 2022[51] - Net revenue for the three months ended December 31, 2023, was $1.2 billion, an increase of 12% compared to $1.03 billion for the same period in 2022[122] - Revenue from the Sleep and Respiratory Care segment for the six months ended December 31, 2023, was $1,980,892 thousand, up 12.4% from $1,761,424 thousand in 2022[30] - Software as a Service (SaaS) revenue for the six months ended December 31, 2023, reached $284,230 thousand, a 27.7% increase from $222,614 thousand in the prior year[30] - Net revenue from Software as a Service (SaaS) increased by 24% to $144.9 million for the three months ended December 31, 2023[125] - Net revenue from devices for the six months ended December 31, 2023 increased to $1,170.7 million, a 10% increase from $1,060.4 million for the same period in 2022[137] Profitability and Earnings - Gross profit for the three months ended December 31, 2023, was $646,934 thousand, compared to $579,715 thousand in Q2 2022, reflecting a 11.6% increase[11] - Net income for the three months ended December 31, 2023, was $208,800 thousand, a decrease of 7.2% from $224,914 thousand in Q2 2022[11] - Basic earnings per share for Q2 2023 was $1.42, down from $1.53 in Q2 2022[11] - The gross margin for the three months ended December 31, 2023, was 55.6%, slightly down from 56.1% in the same period of 2022[122] - Net income for the six months ended December 31, 2023, was $428,222 thousand, compared to $435,392 thousand for the same period in 2022, reflecting a decrease of approximately 1.5%[22] - Non-GAAP net income for the three months ended December 31, 2023, was $277.3 million, compared to $244.4 million for the same period in 2022, an increase of $32.9 million[168] Expenses and Investments - Research and development expenses increased to $73,880 thousand in Q2 2023, up from $69,874 thousand in Q2 2022, indicating a focus on innovation[11] - Selling, general, and administrative expenses for the six months ended December 31, 2023 increased to $445.0 million, a 10% increase from $404.9 million for the same period in 2022[148] - Research and development expenses for the six months ended December 31, 2023 increased to $149.6 million, a 12% increase from $133.1 million for the same period in 2022[153] - The company incurred restructuring expenses of $64.2 million during the three months ended December 31, 2023, compared to no restructuring expenses in the same period of 2022[51] - The company incurred $110,688 thousand in business acquisitions during the six months ended December 31, 2023, compared to $1,011,225 thousand in the same period of 2022[22] Cash Flow and Liquidity - Cash flows from operating activities for the six months ended December 31, 2023, were $559,115 thousand, significantly higher than $173,298 thousand in the same period of 2022[22] - Total cash and cash equivalents at the end of the period were $210,247 thousand, down from $253,199 thousand at the end of December 2022[22] - The company had $955.0 million available for drawdown under the revolving credit facility as of December 31, 2023[72] - Cash provided by operating activities was $559.1 million for the six months ended December 31, 2023, an increase of $385.8 million compared to $173.3 million for the same period in 2022[179] - Cash used in investing activities was $190.1 million for the six months ended December 31, 2023, a significant decrease of $895.1 million compared to $1,085.2 million for the same period in 2022, primarily due to the acquisition of MEDIFOX DAN in 2022[180] Assets and Liabilities - Total assets as of December 31, 2023, were $6,905,088 thousand, an increase from $6,751,708 thousand as of June 30, 2023[8] - Total liabilities decreased to $2,423,234 thousand as of December 31, 2023, from $2,621,805 thousand as of June 30, 2023[8] - Stockholders' equity increased to $4,481,854 thousand as of December 31, 2023, compared to $4,129,903 thousand as of June 30, 2023[8] - As of December 31, 2023, total debt amounted to $1,226.7 million, a decrease from $1,441.1 million as of June 30, 2023[66] Dividends and Share Repurchase - The company declared a dividend of $0.48 per share for Q2 2023, up from $0.44 per share in Q2 2022[11] - The company declared dividends of $141,275 thousand for the six months ended December 31, 2023, compared to $128,931 thousand in the same period of 2022, representing an increase of 9.4%[22] - The company paid cash dividends of $0.48 per common share totaling $70.7 million during the three months ended December 31, 2023[182] - The company has repurchased a total of 7.5 million shares for an aggregate of $462.7 million since the share repurchase program began in 2014, with 335,474 shares repurchased at a cost of $50.0 million during the six months ended December 31, 2023[183] Legal and Regulatory Matters - The Patent Trial and Appeal Board invalidated all challenged claims in the patents asserted by New York University against ResMed in December 2023[83] - ResMed's petition challenging the validity of U.S. Patent No. 10,076,269 was denied by the PTAB, but the decision is pending reconsideration[87] - The first trial in the patent infringement cases filed by Philips against communications module defendants is set for April 1, 2024[86] Market and Economic Conditions - The company is exposed to inflationary pressures that may adversely affect operating results, particularly in maintaining gross margin and operating expenses[205] - A hypothetical 10% change in interest rates would not have had a material impact on pretax income for the three months ended December 31, 2023[204]

ResMed Inc. (NYSE:RMD) Q1 2024 Results Conference Call October 26, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Mick Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Rob Douglas - President and Chief Operating Officer Conference Call Participants David Bailey - Macquarie David Low - JPMorgan Dan Hurren - MST Chris Cooper - Goldman Sachs Craig Wong-Pan - RBC Sean Laaman - Morgan Stanley Margarette Kaczor - William Blair Ste ...

FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ Commission File Number: 001-15317 __________________________________________________________________________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________________ FORM 10-K ___________________________________________________________________________________________ [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 Commission file number: 001-15317 ___________________________________________________________________________________ ...

Unused borrowing capacity $745M $736.7 $351.1 $693.3 LTM 4Q21 LTM 4Q22 LTM 4Q23 Capital Expenditures ($M) Free Cash Flow ($M) $102.7 $134.8 $119.7 LTM 4Q21 LTM 4Q22 LTM 4Q23 $634.0 $216.3 $573.6 LTM 4Q21 LTM 4Q22 LTM 4Q23 Expect liquidity to improve as supply chain environment improves and inventory levels come down 9 © 2023 ResMed | Q4 2023 Earnings Presentation – Aug. 3, 2023 Track record of strong financial returns for shareholders (Financial data as of June 30, 2023) Revenue ($B) Non-GAAP Operating Inco ...

ResMed, Inc. (NYSE:RMD) Q4 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications & IRO Mick Farrell - CEO Brett Sandercock - CFO Rob Douglas - President & COO Lucile Blaise - President, Sleep & Respiratory Care Conference Call Participants Matthew Mishan - KeyBanc Capital Markets Margaret Kaczor - William Blair Anthony Petrone - Mizuho Group Shaymus Contorno - Oppenheimer Laura Sutcliffe - UBS Sean Laaman - Morgan Stanley Lyanne Harrison - Bank of Am ...

ResMed Inc. (NYSE:RMD) Q3 2023 Earnings Conference Call April 27, 2023 4:30 PM ET Company Participants Amy Wakeham - Vice President, Investor Relations Mick Farrell - Chief Executive Officer and Chairman Brett Sandercock - Chief Financial Officer Rob Douglas - President and Chief Operating Officer David Pendarvis - Global General Counsel, Chief Administrative Officer Conference Call Participants Lyanne Harrison - Bank of America Dan Hurren - MST Macquarie Gretel Janu - Credit Suisse Matt Taylor - Jefferies ...

Q3 FY2023 Earnings 3 © 2023 ResMed | Q3 2023 Earnings Presentation – Apr. 27, 2023 During the last 12 months, we changed over 156 million lives* with our digital health products and cloud-based software solutions Our mission is to change 250 million lives in 2025 We're proud to offer digital and connected health solutions that help those with sleep apnea, COPD, and other respiratory diseases live happier, healthier lives in the comfort of home or care setting of their choice Founded 1989 Devices Masks & Oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

ResMed Inc. (NYSE:RMD) Q2 2023 Earnings Conference Call January 26, 2023 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO and Chairman Brett Sandercock - CFO Rob Douglas - President and COO Conference Call Participants Chris Cooper - Goldman Sachs Suraj Kalia - Oppenheimer Matthew Mishan - KeyBanc Capital Markets Steve Wheen - Jarden David Bailey - Macquarie Mike Matson - Needham & Company Craig Wong-Pan - RBC Sean Laaman - Morgan Stanley Margaret Kaczor - W ...